靶向细胞毒疗法：为清除持续性 HIV 感染细胞储库而调整快速发展的抗癌范式。
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.
机构信息
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Curr Opin HIV AIDS. 2011 Jan;6(1):80-5. doi: 10.1097/COH.0b013e3283412515.
Abstract
PURPOSE OF REVIEW
HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described.
RECENT FINDINGS
Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers.
SUMMARY
These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a 'functional cure' whereby therapy can be stopped without viral rebound.
摘要
目的综述
在高效抗逆转录病毒疗法的作用下，持续存在的受 HIV 感染的细胞是从体内清除病毒的最大障碍。本文介绍了旨在选择性杀伤受感染细胞的补充策略。
最近的发现
受癌症领域研究的推动，目前正在开发各种选择性杀伤 HIV 感染细胞的方法。这些方法包括靶向细胞毒性蛋白、过继细胞疗法、溶细胞病毒疗法和靶向非生物药物载体。
总结
这些发展中的努力可能为实现 HIV 清除（即“功能性治愈”）提供关键补充，从而无需病毒反弹即可停止治疗。
相似文献
1
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.靶向细胞毒疗法：为清除持续性 HIV 感染细胞储库而调整快速发展的抗癌范式。
Curr Opin HIV AIDS. 2011 Jan;6(1):80-5. doi: 10.1097/COH.0b013e3283412515.
2
Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.基于靶向杀伤感染细胞的艾滋病治愈方法：针对急性感染与慢性感染的不同策略。
Curr Opin HIV AIDS. 2015 May;10(3):207-13. doi: 10.1097/COH.0000000000000151.
3
Targeted cytotoxic therapy kills persisting HIV infected cells during ART.靶向细胞毒性疗法在抗逆转录病毒治疗期间杀死持续存在的HIV感染细胞。
PLoS Pathog. 2014 Jan;10(1):e1003872. doi: 10.1371/journal.ppat.1003872. Epub 2014 Jan 9.
4
Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.由广泛中和抗体的单链Fv引导的嵌合抗原受体T细胞可特异性有效地根除从接受抑制性联合抗逆转录病毒疗法的HIV-1感染个体分离出的CD4 + T淋巴细胞中潜伏激活的病毒。
J Virol. 2016 Oct 14;90(21):9712-9724. doi: 10.1128/JVI.00852-16. Print 2016 Nov 1.
5
[HIV cure : a realistic perspective ?].[治愈艾滋病：现实的前景？]
Rev Med Liege. 2017 Sep;72(9):388-392.
6
A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.开发抗艾滋病毒药物的新方法：改编非核苷类抗癌化疗药物。
Antiviral Res. 2004 Jan;61(1):1-18. doi: 10.1016/j.antiviral.2003.09.004.
7
HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.HIV 储库：发病机制以及病毒清除和治愈的障碍。
AIDS. 2012 Jun 19;26(10):1261-8. doi: 10.1097/QAD.0b013e328353f3f1.
8
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.Toll样受体7激动剂GS-9620在接受抑制性抗逆转录病毒治疗的HIV感染者细胞中诱导HIV表达和HIV特异性免疫。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.02166-16. Print 2017 Apr 15.
9
Gene therapy for HIV infection.用于治疗HIV感染的基因疗法。
Expert Opin Biol Ther. 2015 Mar;15(3):319-27. doi: 10.1517/14712598.2015.967208. Epub 2014 Oct 17.
10
Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.抗逆转录病毒化合物：高效抗逆转录病毒治疗无法根除HIV-1的潜在机制。
Curr Med Chem. 2005;12(15):1705-19. doi: 10.2174/0929867054367211.
引用本文的文献
1
Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.残余前病毒储存库：HIV持续存在的高风险因素及分析性治疗中断后病毒反弹的驱动因素
Viruses. 2021 Feb 21;13(2):335. doi: 10.3390/v13020335.
2
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.帕比司他对细胞相关HIV RNA和DNA水平及潜伏性HIV感染影响的体内分析。
Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.
3
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?我们能否重新利用美国食品药品监督管理局（FDA）批准的阿法赛特来减少HIV病毒库？
Immunotherapy (Los Angel). 2015 Dec;1(1). doi: 10.4172/imt.1000104. Epub 2015 Nov 30.
4
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.基于CD4设计的新型双特异性嵌合抗原受体，旨在增强抗HIV效力并缺乏HIV进入受体活性。
J Virol. 2015 Jul;89(13):6685-94. doi: 10.1128/JVI.00474-15. Epub 2015 Apr 15.
5
HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.作为治疗靶点的HIV-1 gp120：在动态迷宫中探索
Expert Opin Ther Targets. 2015 Jun;19(6):765-83. doi: 10.1517/14728222.2015.1010513. Epub 2015 Feb 27.
6
Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.基于靶向杀伤感染细胞的艾滋病治愈方法：针对急性感染与慢性感染的不同策略。
Curr Opin HIV AIDS. 2015 May;10(3):207-13. doi: 10.1097/COH.0000000000000151.
7
Targeted cytotoxic therapy kills persisting HIV infected cells during ART.靶向细胞毒性疗法在抗逆转录病毒治疗期间杀死持续存在的HIV感染细胞。
PLoS Pathog. 2014 Jan;10(1):e1003872. doi: 10.1371/journal.ppat.1003872. Epub 2014 Jan 9.
8
Curing HIV: lessons from cancer therapy.治愈 HIV：癌症疗法的启示。
Curr Opin HIV AIDS. 2013 May;8(3):224-9. doi: 10.1097/COH.0b013e32835ef0a1.
9
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.涉及 HIV-1 潜伏期建立的细胞和分子机制。
Retrovirology. 2013 Feb 1;10:11. doi: 10.1186/1742-4690-10-11.
10
Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.抗 HIV 双可变区免疫球蛋白结合 gp41 和 gp120 用于免疫缀合物的靶向递送。
PLoS One. 2012;7(10):e46778. doi: 10.1371/journal.pone.0046778. Epub 2012 Oct 4.
本文引用的文献
1
AIDS/HIV. A boost for HIV vaccine design.艾滋病/艾滋病毒。对艾滋病毒疫苗设计的推动。
Science. 2010 Aug 13;329(5993):770-3. doi: 10.1126/science.1194693.
2
Adoptive cell therapy: genetic modification to redirect effector cell specificity.过继细胞疗法：基因修饰以重新定向效应细胞特异性。
Cancer J. 2010 Jul-Aug;16(4):336-41. doi: 10.1097/PPO.0b013e3181eb3879.
3
Design of virotherapy for effective tumor treatment.用于有效肿瘤治疗的病毒疗法设计。
Curr Opin Mol Ther. 2010 Aug;12(4):403-11.
4
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.自体 T 细胞经基因工程改造后识别 CD19，用于治疗患者，可消除 B 细胞系细胞并使淋巴瘤消退。
Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.
5
Antibody-drug conjugates: targeted drug delivery for cancer.抗体药物偶联物：癌症的靶向药物递送。
Curr Opin Chem Biol. 2010 Aug;14(4):529-37. doi: 10.1016/j.cbpa.2010.06.170. Epub 2010 Jul 17.
6
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.嵌合抗原受体（CAR）疗法需要驾驶执照吗？采用嵌合抗原受体重定向T细胞的过继性细胞疗法已引发严重不良事件。
Hum Gene Ther. 2010 Sep;21(9):1039-42. doi: 10.1089/hum.2010.131.
7
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.HIV 持续存在以及 HIV 感染者实现长期无药物缓解的前景。
Science. 2010 Jul 9;329(5988):174-80. doi: 10.1126/science.1191047.
8
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.锌指核酸酶靶向 CCR5 修饰的人造血干/祖细胞可在体内控制 HIV-1。
Nat Biotechnol. 2010 Aug;28(8):839-47. doi: 10.1038/nbt.1663. Epub 2010 Jul 2.
9
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.高效抗逆转录病毒治疗（HAART）的免疫毒素互补作用以清除持续存在的HIV感染细胞储存库。
PLoS Pathog. 2010 Jun 10;6(6):e1000803. doi: 10.1371/journal.ppat.1000803.
10
Building better chimeric antigen receptors for adoptive T cell therapy.构建更好的嵌合抗原受体用于过继性 T 细胞疗法。
Curr Gene Ther. 2010 Apr;10(2):77-90. doi: 10.2174/156652310791111001.
Zotero 插件